Baroda Children Eyecare and Squint Clinic, Vadodara, Gujarat, India.
Indian J Ophthalmol. 2022 Jan;70(1):238-240. doi: 10.4103/ijo.IJO_1462_21.
Low-concentration atropine (LCA; 0.01%) is known to reduce the progression of myopia in axial myopes. The purpose of this study was to understand the role of LCA in premyopic children in preventing progression.
A randomized case-control study of known premyopes was done between the use of LCA and no intervention. A total of 30 children were included in both groups.
The mean age in the LCA group was 7.7 ± 2.1 years (5-12 years), and in the control group, it was 7.2 ± 1.9 years (4-12 years). The mean baseline progression per year in the LCA group (before starting the eye drops) was - 0.72 ± 0.3 D, and in the control group, it was - 0.69 ± 0.4 D. At the end of the first year, the mean progression in the LCA group was - 0.31 ± 0.3 D versus - 0.76 ± 0.4 D, and the axial length increase was 0.12 ± 0.1 mm in the LCA group and 0.21 ± 0.2 mm in the control group. At the end of the second year, the mean progression compared with the baseline in the LCA group was - 0.6 ± 0.3 D versus - 1.75 ± 0.4 D, and the axial length showed an increase from baseline in the LCA group by 0.21 ± 0.2 mm, and in the control group, the increase was 0.48 ± 0.2 mm in 2 years.
Low-concentration eye drops (0.01%) work in preventing the progression of axial myopia in premyopic children.
低浓度阿托品（LCA；0.01%）已知可减缓轴性近视的进展。本研究旨在了解 LCA 在预防近视前期儿童进展中的作用。
对使用 LCA 和不干预的已知近视前期儿童进行随机病例对照研究。两组各纳入 30 名儿童。
LCA 组的平均年龄为 7.7 ± 2.1 岁（5-12 岁），对照组为 7.2 ± 1.9 岁（4-12 岁）。LCA 组基线时每年的平均进展量为 - 0.72 ± 0.3 D，对照组为 - 0.69 ± 0.4 D。在开始滴眼药水前的第一年，LCA 组的平均进展量为 - 0.31 ± 0.3 D，而对照组为 - 0.76 ± 0.4 D，LCA 组眼轴长度增加 0.12 ± 0.1 mm，对照组增加 0.21 ± 0.2 mm。第二年结束时，与 LCA 组的基线相比，平均进展量为 - 0.6 ± 0.3 D，而对照组为 - 1.75 ± 0.4 D，LCA 组眼轴长度从基线增加 0.21 ± 0.2 mm，而对照组增加 0.48 ± 0.2 mm。
低浓度眼药水（0.01%）可预防近视前期儿童轴性近视的进展。
